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Direcţii posibile de dezvoltare a industriei farmaceutice în Republica Moldova
Industria farmaceutică este una dintre ramurile prioritare în economia mondială. Pentru Republica Moldova, ţară cu un potenţial ştiinţific 
adaptat modest la elaborarea şi la implementarea în practică a medicamentelor, aceasta este o ramură strategică. Cinci direcţii de dezvoltare a 
industriei farmaceutice sunt prioritare în Republica Moldova şi în alte state, cu un potenţial economico–financiar similar. Elaborarea, producerea 
şi implementarea în practica terapeutică a medicamentelor originale, care necesită alocaţii financiare impunătoare şi un potenţial ştiinţific 
înalt–calificat, în prezent depăşeşte posibilităţile ţărilor în curs de dezvoltare. Fabricarea produselor generice constituie 90% din producţia de 
medicamente autohtone. Noile combinaţii de substanţe active cunoscute prezintă un aspect cost/eficienţă/ inofensivitate actual pentru terapeutica 
modernă. A patra direcţie de perspectivă în industria farmaceutică este elaborarea unor principii active, cu proprietăţi fizico-chimice modificate, 
care ar micşora riscul efectelor nedorite (alergizarea) şi, prin urmare, ar ameliora tratamentul. O importanţă indiscutabilă prezintă implementarea 
în practica medicală a produselor destinate terapiei personificate, cu folosirea realizărilor moderne din domeniul farmacogeneticii.
Cuvinte–cheie: medicament original, medicament generic, medicament combinat.
Возможные направления развития фармацевтической промышлености в Республике Молдова
Фармацевтическая промышленость является одной из приоритетных отраслей в мировой экономике. Для Республики Молдова, 
при существующей квалификации научного потенциала в области разработки и внедрения лекарственных средств, данная отрасль 
является стратегически важной. Были выявлены пять возможных направлений развития фармацевтической промышлености в 
Молдове и в странах с аналогичным финансово-экономическим положением. Производство и внедрение в терапевтическую практику 
новых оригинальных лекарств, требующих значительных финансовых капиталовложений и высококвалифицированного научного 
потенциала, является важным направлением. Производство генериков составляет около 90% фармацевтической продукции в Республике 
Молдова. Новые комбинации активных веществ с их терапетическим потенциалом – это многообещающее направление в развитии 
лекарственного производства. Весьма перспективной представляется и разработка новых активных препаратов с измененными 
физико–химическими свойствами, позволяющих уменьшить риск побочных эффектов (аллергизации) и, как следствие, повысить 
эффективность лечения. Несомненную роль сыграет внедрение в медицинскую практику лекарственных средств, предназначенных 
для персонифицированной фармакотерапии с использованием достижений в области фармакогенетики.
Ключевые слова: оригинальное лекарство, генерическое лекарство, комбинированное лекарство.
Introduction
A drug is defined as a chemical substance or psychogenic 
factor which after being introduced into the human or animal 
body in an adequate dose, cures and/or ameliorates particular 
symptoms of an illness or medical condition, or which may 
be used as preventive medicine which does not treat exist-
ing or pre-existing diseases or symptoms, or which can be 
used for diagnosis of a disease, or used to otherwise enhance 
physical or mental well-being. The drug should be licensed 
for production and authorized for medical use and placed 
on the pharmaceutical market in several countries which are 
members of WHO [1].
Some governments define the term drug by law. In the 
United States the definition of “drug” in the Federal Food, 
Drug, and Cosmetic Act includes “articles intended for use 
in the diagnosis, cure, mitigation, treatment, or prevention of 
disease in man or other animals” and “articles (other than food) 
intended to affect the structure or any function of the body of 
man or other animals.” Consistent with that definition, the U.S. 
separately defines narcotic drugs and controlled substances, 
which may include non-drugs, and explicitly excludes tobacco, 
caffeine and alcoholic beverages. 
A medicinal product is defined in amended Directive 
2001/83/EC as:
‘… any substance or combination of substances presented 
as having properties for treating or preventing disease in human 
beings… [or] any substance or combination of substances which 
may be used in or administered to human beings either with a view 
to restoring, correcting or modifying physiological functions by 
exerting a pharmacological, immunological or metabolic action, 
or to making a medical diagnosis’[2].
“Drug” is thought to have originated from Old French 
“drogue”, possibly deriving later into “droge-vate” from Middle 
Dutch meaning “dry barrels”, referring to medicinal plants 
preserved in them.
Three major demographic trends in the developed world-
aging population, increased life expectancy, and increased 
incidence of chronic diseases-make for ideal conditions for 
increased used of medicines (Table 1).
The increased used of medicines will have important 
consequences for consumers. First, morbidity and mortality 
will be reduced. According to a study by the London-based 
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Office of Health Economics, pharmaceuticals will account for 
10 to 40 percent of future reductions in heart disease mortality, 
15 to 40 percent in cerebro-vascular disease, 28 to 65 percent 
in breast cancer, and 3 to 26 percent in lung cancer. Second, 
medical costs will be reduced. According to estimates by the 
National Bureau of Economic Research, based in Cambrige, 
MA, USA, replacing older medicines with newer ones increases 
drug spending by an average of $18 but reduces other health-
care costs by $129, resulting in a net saving of $111 per person. 
Finally, greater use of medicines will create an increased quality 
of life for consumers (Fig. 1). 
Table 1
World trade in pharmaceuticals, 2007, billion £
Country Exports £ Imports £ Balance £
Switzerland 20,206 9,336 10,870
Ireland 9,664 1,520 8,144
Germany 24,395 18,810 5,586
UK 14,567 10,291 4,276
France 13,675 10,135 3,540
Sweden 4,726 1,731 2,995
Netherlands 7,439 7,276 0,163
Italy 7,607 8,466 -859
Spain 4,142 5,227 -1,085
Japan 1,736 4,625 -2,889
USA 17,491 35,801 -18,310
Source:  EFPIA – European Federation of Pharmaceutical 
Industries and Associations, JPMA – Japan Pharmaceutical 
Manufacturers Associations, US Census Bureau,UK Customs 
and Excise 
Industry studies claim that newer medicines contribute to 
reduced hospitalizations and surgery, fewer adverse effects from 
medication, decreased complications of disease, and increased 
worker productivity [3]. 
In a global industry such as pharmaceuticals, it is impor-
tant to be among the top group of the world’s pharmaceutical 
producers (Table 2). 
Table 2
top world pharmaceutical corporations, 2007
Company Country Sales billion £
Growth* 
%
Market 
share** %
Pfizer USA 22,292 -2 6.7
GlaxoSmithKline UK 18,847 1 5.6
Novartis SWI 17,154 9 5.1
Sanofi Aventis FRA 16,788 8 5.0
Astrazeneca UK 15,010 9 4.5
Johnson & Johnson USA 14,478 5 4.3
Roche SWI 13,814 18 4.1
Merck & Co USA 13,631 8 4.1
Abbott USA 9,570 8 2.9
Lilly USA 8,335 13 2.5
Leading 10 149,920 6 44.9
Amgen USA 8,188 1 2.5
Wyeth USA 7,949 8 2.4
Bayer GER 7,020 13 2.1
Bristol-Myers Squibb USA 6,519 6 2.0
Boehringer Ingelheim GER 6,277 11 1.9
Schering-Plough USA 6,181 10 1.9
Takeda JAP 5,479 9 1.6
Teva ISR 5,300 12 1.6
Novo Nordisk DEN 3,336 18 1.0
Daiichi Sankyo JAP 2,925 7 0.9
Leading 20 209,093 7 62,6
Notes:  By worldwide sales value, *calculated in US$, ** 
IMS (Intercontinental Marketing Services) audited markets; 
Source:  IMS (Intercontinental Marketing Services)
An analysis of the world’s top 100 medicines reveals that, 
after the USA, Britain’s pharmaceutical companies’ market share 
is more than all its European competitors combined (Fig. 2) [3].
There are five development pathways in the pharmaceuti-
cal industry.
I.  the synthetic or classical development pathway of 
drug development
Fig. 1.  Annual medicines expenditure per person, 2007.
Notes:  £ per person, Includes prescription and hospital medicines; Source:  IMS (Intercontinental Marketing Services) World Review, 
United Nations, World Population Prospects, Office for National Statistics
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The classic paradigm of synthetic drug development 
consists of four steps: drug discovery and design, preclinical 
and clinical studies. This paradigm results in a drug-develop-
ment process that is high risk, time-consuming, and expensive. 
The process requires screening an average of 10,000 active 
compounds to find a single compound that successfully 
makes its way through validation to drug approval and the 
marketplace. 
The potential of new molecules in drug development 
is judged on the basis of the benefit/risk ratio. Preclinical 
safety – which includes the classical toxicology disciplines and 
safety pharmacology, immunotoxicology, drug metabolism and 
pharmacokinetics –is an important dimension for comparing 
similar molecules and helps in the selection of molecules with 
superior chance for a successful development. New in silico 
or in vitro methods are available or are under development 
which makes possible a much more rapid assessment of a series 
of compounds for major liabilities (e.g., genotoxicity, major 
organ toxicities, teratogenicity, immune system perturbations, 
drug-drug interaction potential).  Early safety evaluation takes 
advantage of these new tools to build a testing strategy which 
begins with target assessment and extends to lead compound 
optimization and the selection of clinical candidates.  Starting 
with in silico techniques (verification of databases to detect 
structural alerts; and also modeling, etc.) and in vitro methods 
(enzymatic or cellular models, preferably with humanized 
cell lines) applied methods become more complex (e.g. in 
vivo imaging) and as result the selection of potential drug 
candidates in a project narrows. These tests are intended to 
support science-based decisions and target the nature of the 
molecule under consideration taking all previous experience 
with a compound class into account. Today in vitro methods 
are not ready to replace in vivo testing entirely because results 
are limited by the uncertainty of extrapolation to a whole or-
ganism and the human species. However, they allow to focus 
in vivo evaluations to the relevant questions, support selection 
of the most promising clinical products, help in refining study 
designs and overall allow to reduce the amount of required in 
vivo animal and human testing. 
Pharmaceutical R&D is a highly complex set of processes 
in which uncertainty and risk persist throughout long cycles 
of discovery and development. On average the development of 
safe and effective medicines takes 12 -15 years at a total cost 
that is now approaching $1 billion per product. Productivity for 
the industry as a whole, as measured as total cost per approved 
drug, has declined. Although many internal and external fac-
tors contribute to this lowered rate of productivity clearly one 
approach to address this issue is redesigning the R&D engine 
to increase the rate of innovation and development of new 
products at a lower cost to meet medical needs [4,5,6,7]. 
The highly expensive development process of original 
drugs makes it unaffordable for pharmaceutical industries of 
CIS countries, including Republic of Moldova.  There will be 
fewer originators of new therapeutic classes of drugs such as 
Morton’s Ether, Sir Fleming’s Penicillin, Domagk’s Prontozile, 
Sertürner’s Morphine, Banting and Best’s Insulin. It is only with 
some skepticism that we consider the domestic drugs Izoturone, 
Pacovirine, Pimistimuline-3, BioR etc. as original products.
II.  Generic production
The ongoing need to provide the population of the 
Republic of Moldova with cost-effective pharmacological 
therapies has led to an emergent public health initiative in this 
country for the production of generic versions of therapeutic 
products. Generics have historically afforded considerable sav-
ings to the consumers in need of prescription and OTC medica-
tion. A recent report issued by the US Department of Health & 
Human Services estimates that generic drugs constitute 63% 
of the total prescription medicines sold in the US. The report 
also stated that generic drugs cost approximately 11% of the 
total cost of branded pharmaceuticals (on a per – dose basis) 
[8]. According to the Congressional Budget Office, generic 
drugs save consumers an estimated $8 to $10 billion a year at 
retail pharmacies.  Even more billions are saved when hospitals 
use generics [9].
Therefore, generic drugs can save patients and insurance 
companies substantial costs. The relatively low price of generics 
is determined by the fact that: 
- Manufacturers do not incur the cost of drug discovery;
- Manufacturers do not have to prove the safety and 
efficacy of the drugs through clinical trials (although they have 
to conduct bioequivalence study);
- Manufacturers do not incur marketing efforts, includ-
ing media advertising, presentations by drug representatives, 
and distribution of free samples;
- Many generic drugs are already well-known to pa-
tients and providers (although under their branded name);
- Competition increases among producers when drugs 
no longer are protected by patents.
As manufacturers incur fewer costs in producing the ge-
neric drug and are therefore able to maintain profitability while 
Fig. 2.  Sales share of the world’s top 100 prescription medicines 2007.
Source:  IMS (Intercontinental Marketing Services)
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offering the drug at a lower price to consumers. The costs of the 
majority of generic drugs are quite low and many developing 
countries can easily afford their manufacturing. For example, 
the Republic of Moldova manufactures a number of generic 
products, amoxicilline, azitromicin, captopril, carbamazepin, 
ceftazidime, clotrimazole, diclofenac, metoprolole, lisinopril, 
indapamid, ranitidin, spironolacton, tramadol, etc.  
The pharmaceutical drug production process is easily 
replicated and a generic drug product is virtually identical to 
the original. According to the legislation of many countries, 
generic drugs are identical or bioequivalent to the brand name 
counterparts in their pharmacokinetic and pharmacodynamic 
properties. By extension, therefore, generics are identical in 
their indented use, dose and strength, route of administration, 
safety, and efficacy. The drug’s sponsor must show that a ge-
neric drug delivers the same amount of its active ingredient in 
the same amount of time as the trade-name counterpart. This 
bioequivalence is critical for proving that both the original and 
generic drugs will produce similar therapeutic results [9]. 
In most cases, generic products are available once the 
patent protections afforded to the original developer have 
expired. When generic products become available the market 
competition often leads to substantially lower prices for both 
the original brand name product and the generic forms. The 
time it takes a generic drug to appear on the market varies. In 
the US, drug patents give twenty years of protection, but they 
are applied for before clinical trials begin, so the effective life 
of a drug patent tends to be between seven and twelve years. 
The expiration of a patent removes the monopoly of the pat-
ent holder on drug sales licensing. Actually, there is no way 
to renew a patent after it expires. A new version of the drug 
with significant changes to the compound could be patented 
but this requires new clinical trials. In addition, a patent on a 
changed compound does not prevent sales of the generic ver-
sions of the original drug unless regulators take the original 
drug off the market. This allows the company to recoup the cost 
of developing that particular drug. After the patent on a drug 
expires it can be manufactured and sold by any pharmaceutical 
company. Since the drug has already been tested and approved 
the cost of simply manufacturing the drug will be a fraction of 
the original cost of developing that particular drug.
Generally, the people of the Republic of Moldova have 
more confidence in imported brands which are more expensive 
than locally produced pharmaceuticals, but with the growing 
economic uncertainties and budgetary constraints more con-
sumers are expected to turn to local brands. 
Meanwhile, increasingly health-conscious Moldavians are 
contributing to the growth of herbal and traditional medicines, 
a desire that is undeterred by the current economic environ-
ment. This trend is attributed to consumers’ preference for 
self-administered healthcare, the prevalence of chronic illnesses 
that cannot be cured by conventional drugs, and the high pace 
of life which induces higher levels of stress. Consumers are 
increasingly turning from synthetic allopathic drugs (conven-
tional drugs) to herbal products to maintain health and prevent 
illnesses. The rich biological heritage of Republic of Moldova 
presents a potential for the local pharmaceutical industry to 
lead in the herbal market. Many local players have already 
ventured into this arena, especially with the encouragement 
from the Government through various grants and incentives 
for R&D in the use of herbal products.  Some of these are: 
Amniocen, Coriocen, Todicamp, Pimistimulin–3, Pacovirin, 
BioR, Fibrofit, Imupurin, Medicas E, Enoxil, etc. 
III.  New combinations
The concomitant use of medicinal products may trigger 
the development of a fixed combination product which manu-
facturers believe will be more convenient for the consumers 
and ultimately improve compliance. Four main scenarios can 
be identified: the combination of well-known compounds 
already approved/used in combination; the combination of 
approved/well known compounds not previously approved in 
combination; the combination of one or more new chemical 
entity(ies) [NCE] with one or more well known compound(s); 
and the combination of two or more NCEs. 
Almost half of marketed drugs are fixed combination 
preparations. Advantages of fixed combination preparations 
include: increased compliance, synergy, increased efficacy, 
reduced side-effects and lowered cost. Potential disadvantages 
include an inflexible fixed dose ratio and the possibility of 
incompatible pharmacokinetics and increased toxicity.  More-
over, the physician or pharmacist – or both – may be ignorant 
of the totality of the medicine’s contents.  Some combinations 
of undisputed value are oral contraceptives, levodopa with 
decarboxylase inhibitors, pyrimethamine with sulphadoxine, 
etc. In other cases fixed-dose combinations may have value in 
strictly specified circumstances, but probably in some cases 
are over-prescribed. There is also widespread, unjustified use 
of combinations in over-the-counter preparations which may 
have unforeseen adverse effects.  Combinations should only 
be used if each component is necessary for the desired effect 
and if the advantages outweigh the added risks of using 2 or 
more drugs. Before prescribing combination drugs, clinicians 
should always ask themselves a series of questions, of which 
the most important is whether the patient needs each drug in 
a particular combination, or if 1 component alone would suf-
fice. In general, government regulatory bodies in developed 
countries are attempting to curb the use of combination drugs, 
but a better approach might be to better educate doctors on 
both the advantages and disadvantages of fixed combination 
preparations which would lead to improved methods of pre-
scribing these drugs.
Neamon–hepa, taken in capsule form, is a pharmaceuti-
cal combination now being studied at The Scientific Center 
of Medicines of the Republic of Moldova. The drug is used 
in hyperammonemic conditions (the high concentration 
of ammoniac in the blood and especially in the brain). It is 
well–known that the main toxin in severe hepatic dysfunc-
tion (active chronic hepatitis, cirrhosis, encephalopathy and 
hepatic coma) ammoniac is not metabolized into urea due to 
albuminous failure. Neamon–hepa is prescribed in general 
conditions of physical and mental weariness associated with 
an albuminous failure, in specific asthenic conditions during 
convalescence.  Capsulated Neamon–hepa is a pharmaceutical 
combination containing Spironolactone, Arginine aspartate 
and BioR.  Spironolactone is a well-known K+ saving diuretic; 
Arginine aspartate a tonic substance used in hyperammonemic 
conditions, mental and physical asthenia; and also in certain 
memory disturbances; and BioR a spiruline micro-algae 
extract (extremely rich in vitamins, minerals and enzymes). 
The new pharmaceutical composition is intended to provide a 
combination of active substances which is super-additive and 
synergistic. Nevertheless, no additional side-effects are experi-
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enced. The therapeutic effect of the combination corresponds 
approximately to the maximum achievable improvement.  The 
principal advantage of the combination is the improved adher-
ence to treatment due to the simplification of the regimen.  This, 
in turn, should result in higher levels of efficacy.  The main 
disadvantage is the inflexibility of the dosage.
The issues to consider when initiating a new regimen are 
potency, tolerability, convenience, coburdens, long-term toxici-
ties, and future therapeutic options.  Each participant (patient, 
physician and pharmacist) should be involved in determining 
the balance of these questions.  Actually, these are the questions 
that play a large role in determining how patients accept new 
therapies that is the patient’s ability to tolerate the drug and its 
overall convenience while physicians must consider potency, 
long-term toxicities, and future treatment options.
Also on the horizon is the issue of patients’ co-payments 
for fixed-dose combinations.  Obviously it is simpler for pa-
tients with third-party payers to make one co-payment for 3 
drugs than separate co-payments for each. Finally, it is more 
convenient and economical for the provider to explain one 
instruction to the patient than several – one aspect of the grow-
ing issue of cost-effectiveness doctors must face in consulting 
with their many patients.  
IV.  Reducing the incidence of adverse reactions by 
modifying the drug’s physical and chemical properties (e.g. 
allergenic properties of xenobiotics).
Many new drugs are expected to be developed in the 
coming years. Advances in technology and the knowledge of 
how cells and xenobiotics inter-react will allow pharmaceutical 
manufacturers to become more efficient in the R&D process. 
New technology allows life scientists to test drug candidates 
far more rapidly than in the past. Based on empirical observa-
tions, a correlation has been established and an index proposed 
to relate the physical properties of medicinal substances and 
their allergenic potentialities. This index, based on the physical 
properties of the substance (melting point, solubility, molecular 
weight, dose, etc.) has been verified on a series of commonly 
known drugs. 
The allergenic index (indicating the probability of allergic 
reactions) directly correlates the molecular weight, dose and 
melting point of the substance, and indirectly with its solubility 
in water and/or lipids.
The formula of allergenic index is:
I = (0,001M + 0,5d + 0,01T) / 0,1S
where: I – allergenic index,
M – molecular weight of the substance,
d – dose in grams,
T – melting point in degrees Celsius, and
S – solubility in water or lipids g/100 ml.
The parameter I may have a wide range of variations, in 
which values lower than 1,0 indicate low allergenic character 
while values higher than 1,0 indicate the opposite.
Substances were selected in order to establish values for 
M, d, T, and S included at certain intervals and they were then 
separated into two groups, each of about 300 active substances. 
The average index I and the percentage showing the allergenic 
properties are presented in Table 3. 
The allergenic index calculated from the proposed 
formula gives 0,44 for the first group and 3,24 for the 
second.
Table 3
Allergenic index of drugs with the melting point  
up to 1000C compared to those with melting point 
 higher than 2000C
M d T S I
% with 
allergenic 
properties
106 ± 16,9 0,35 ± 0,078 48,8 ± 3,92 19,7 ± 3,92 0,44 3
352 ± 40,1 0,42 ± 0,01 245 ± 5,4 9,3 ± 2,44 3,24 70
Table 4
Allergenic index for nicotinic acid and its derivatives
Substance M d T S I Allergenic 
Nicotinic acid 123 0,1 236-238 70 19,6 Strong
Nicotinamid 122 0,1 130-132 10 1,5 Weak
Nicotinic acid  
dimethylamide 132 0,5 20-25 0,1 0,14 No
The proposed formula allows a pharmaceutical manufac-
turer to estimate the potential of the drug/substance to develop 
allergenic properties.
Another example was chosen for nicotinic acid and two 
of its derivatives (Table 4). 
We can see that the higher the value of I the higher are 
the allergenic properties of the drug. The allergenic index cor-
relates well with the allergenic effects of different compounds; 
therefore, if the index is higher than 1,0 the xenobiotics have 
a potential to produce allergic reactions[12].  
The characteristics of substances with a high allergenic 
index show that they tend to have high molecular weight, a high 
melting point and low solubility.  These factors indicate the strong 
possibility that these compounds will be found in the body as solid 
particles, possibly as molecule associations or microcrystals, not 
as molecular solutions.  As a result the antigen processing and 
presenting cells (such as macrophages or dendritic cells) will 
react more actively and increase the immune response of the 
body. Certainly, the chemical composition of xenobiotics is es-
sential in manifesting allergenic potential. The solubility, melting 
point, and aggregation state of xenobiotics greatly influence the 
“recipient’s”   reaction. Substances with melting points higher than 
2000C have enhanced allergenic properties compared to those 
substances with melting points lower than 1000C. Drugs with 
high allergenic potential are approximately 180 times less soluble 
in water than substances which do not manifest allergenic proper-
ties.    Liposoluble substances behave similarly. Macromolecular 
compounds (proteins, mucopolysaccharides), large molecules 
presenting associations of molecules which are not ionized in 
organisms, also manifest a higher allergenic potential.  Pharma-
codinamic properties of drugs are influenced by the aggregation 
state of the substance. Crystalline substances are more allergenic; 
amorphous powders, liquids and gases, especially, are not. The 
stronger the intermolecular power the higher the possibility of 
allergic reactions. The formula shows that the allergenic index 
is dose - dependent – a larger amount of substance may act as a 
stronger allergen [13].
V.  Personalized healthcare possible through the 
achievements of modern pharmacogenetics
The rapidly growing understanding of the molecular 
bases of disease pathology, aided by progress in genomics and 
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genetics, provides medical sciences with numerous new insights 
into the differences among patients and a more informative and 
accurate taxonomy of the states of a disease.  Large population 
differences with small individual differences are consistent with 
the role of heredity as a determinant to a patient’s response to a 
given drug.  It is estimated that genetics can account for 20 to 
95 percent of the variability of the drug’s disposition and effects 
[14, 15]. Medical professionals are able to develop appropriate 
tests and drugs for specific diseases and disease subgroups 
to create medicines that are more effective and safe. This is 
“personalized healthcare” or “personalized medicine”. With the 
knowledge of the individual characteristics of patients and their 
diseases, personalized healthcare professionals are able to tar-
get medicines more precisely. This personalized medicine can 
help professionals avoid prescribing patients medicines from 
which they are unlikely to benefit, and from exposure to the 
side-effects of a particular treatment. In some cases it will also 
be possible to identify patients who have a higher likelihood 
suffering side-effects who can then be treated with less risky 
therapies. In 2004, Pirmohamed et al. published an analysis 
of the impact of adverse drug reactions (ADRs) on two large 
Merseyside NHS (National Health Service) hospitals over six 
months. They found that 6,5 % of over 18.000 admissions were 
due to ADRs, and projected that the annual cost to the NHS was 
around ₤ 466 m. Most of these events were thought avoidable 
with the main culprits being low-dose aspirin, warfarin, other 
non–steroidal anti–inflammatory drugs and diuretics [16].
 This approach to healthcare promises many benefits: 
• Patients and physicians will benefit by being able to 
make safer, more effective and more rational therapy choices. 
(Example: drugs such as 6-thioguanine are widely used in on-
cology, dermatology and other specific fields of medicine. These 
have a number of potentially serious side effects, including fatal 
myelosuppresion. Metabolism of these drugs is performed pri-
marily by the enzyme thiopurine S-methyltransferaze (TPMT), 
although others are involved, including methylenetetrahydro-
folate reductase. A number of common polymorphisms in the 
TPMT gene determine the level of enzyme activity. Individuals 
with low or intermediate activity are at risk of drug toxicity 
unless the drug dose is reduced, usually to about 10 per cent 
of standard doses) [17]. The reduction of uncertainty related to 
the potential danger of adverse side-effects will likely improve 
patient compliance and the patient-physician relationship, and 
shorten the duration of the therapy. 
• Healthcare systems will benefit by reducing the bur-
den of administering therapies to patients who have little or 
no chance of deriving benefit and by reducing the impact of 
avoidable adverse drug reactions. Pre-treatment genetic tests 
have been carried out in the U.S. for approximately 10 years, 
and there is evidence to suggest that it is cost-effective in cer-
tain health care settings. One of the difficulties of transferring 
testing to other countries is that there are around 13 known 
alleles associated with reduced TMPT activity, first identified 
in predominantly Caucasian patients. However, these variants 
have different frequencies in different population groups as 
well as variations in functional effects between heterozygous 
and homozygous individuals, suggesting that other genetic or 
environmental factors have a role in determining the response 
to particular drugs [17].  Whether or not this will lead to net 
cost savings by healthcare systems is difficult to say as they will 
have to incur the cost of testing in order to reap these benefits 
– but personalized medicine does represent a more rational 
and cost-effective approach to healthcare.
The discovery and development of new drugs is expen-
sive and risky. Most fail in early clinical trials, with a common 
failure rate of around 97-99 %.  Pharmacogenetics could help in 
reducing high failure rates and development costs by identify-
ing potential responders and non-responders to a drug at an 
early stage by using genetic variants that are markers of drug 
efficacy [17].
There is a direct relationship between gene discovery 
and identification of new drugs — the more genes identified 
the more paths available for drug discovery. Data obtained 
from the mapping of the human genome can be compared 
with known gene sequences to identify the proteins produced 
by each gene and the effect of those proteins on the body. The 
study of these gene sequences and the varieties of proteins they 
produce contributes to the development of new medicines, both 
biotechnological and chemical. Among other uses, new genetic 
technology is being explored to develop vaccines to prevent 
or treat diseases such as AIDS, malaria, tuberculosis, etc., the 
cures of which have eluded traditional vaccines. 
In order to draw health professionals and patients at-
tention to the importance of pharmacogenetics issue, we have 
proposed to complement patient information leaflet with a 
facultative component: elements of personalized pharmaco-
therapy.
The pharmaceutical industry of Republic of Moldova 
is far from being the leading manufacturing sector either in 
this country or in the global pharmaceutical industry.  For 
Moldovian pharmaceutical companies to become significant 
manufacturers requires many steps in development, flexibility, 
and the willingness to undertake risks, all necessary if it is to 
build a strong, growing and globally successful pharmaceuti-
cal industry.
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